Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 285 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Parasitic Diseases Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine

NCT00427167
View directory record Official record
Conditions
Malaria
Interventions
AMA1-C1/Alhydrogel + CPG 7909 (Saline), AMA1-C1/Alhydrogel + CPG 7909 (Phosphate), AMA1-C1/Alhydrogel + CPG 7909
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 7:15 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis

NCT01140191
View directory record Official record
Conditions
Leishmaniasis, Cutaneous
Interventions
WR 279,396
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Not applicable Interventional

Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients

NCT00002062
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Spiramycin
Drug
Lead sponsor
Rhone-Poulenc Rorer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Horsham, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Experimental Vaccine for Plasmodium Falciparum Malaria

NCT00340431
View directory record Official record
Conditions
Plasmodium Falciparum Malaria, Vaccines
Interventions
MSP1(42)-FVO & MSP1(42)-3D7
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tafenoquine Thorough QTc Study in Healthy Subjects

NCT01928914
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg, moxifloxacin, Placebo for Tafenoquine, Placebo for moxifloxaxin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Culver City, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women

NCT01230814
View directory record Official record
Conditions
Bacterial Vaginosis, Candidiasis, Trichomoniasis
Interventions
Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Oct 25, 2026, 7:15 PM EDT
Completed No phase listed Observational

Study of Patients With Strongyloides Stercoralis Infection

NCT00001245
View directory record Official record
Conditions
HIV Infection, Nematode Infection, Strongyloidiasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 80 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1989
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 1 Interventional

A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea

NCT00001018
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Letrazuril
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation

NCT01336647
View directory record Official record
Conditions
Pediculosis
Interventions
Group A - Low-Dose Ha44 0.37% w/w, Group B - High Dose Ha44 Gel 0.74% w/w, Group C - Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
2 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Dinuba, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

NCT01366534
View directory record Official record
Conditions
Malaria
Interventions
Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01), GSK Biologicals' malaria vaccine 257049 (2 doses), GSK Biologicals' malaria vaccine 257049 (3 doses), Sporozoite challenge
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 25, 2026, 7:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Maternal and Child Health Through Point-of-care STI Testing

NCT07290439
View directory record Official record
Conditions
Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
Interventions
Point-of-care STI tests, Standard of care STI testing
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
Female only
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 7:15 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

NCT01940757
View directory record Official record
Conditions
Hookworm Infection
Interventions
Necator americanus Hookworm Larvae
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AMA1-C1/Alhydrogel + CpG 7909 for Malaria

NCT00344539
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multimedia WORTH With Black Drug-Involved Women on Probation

NCT02391233
View directory record Official record
Conditions
Sexually Transmitted Infections, HIV, Gonorrhea, Trichomonas, Chlamydia Trachomatis, Drug Use
Interventions
E-WORTH, Streamlined HIV Testing
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

NCT00312702
View directory record Official record
Conditions
Malaria, Plasmodium Falciparum Malaria
Interventions
Falciparum Malaria Protein 11 with AS02A adjuvant
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%

NCT03257943
View directory record Official record
Conditions
Lice; Head Lice
Interventions
Ivermectin Lotion, 0.5%, SKLICE (ivermectin) Lotion, 0.5%, Vehicle of the Test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation

NCT02060903
View directory record Official record
Conditions
Head Lice Infestation
Interventions
Abametapir Lotion 0.74% w/w, Vehicle Lotion
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
6 Months and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Dinuba, California • Los Angeles, California • West Palm Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans

NCT00935623
View directory record Official record
Conditions
Plasmodium Vivax Malaria
Interventions
Malaria Challenge
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Efficacy and Safety of ABO809 in Healthy Participants

NCT05036668
View directory record Official record
Conditions
Cryptosporidium Infection, Cryptosporidiosis
Interventions
Cryptosporidium parvum oocysts (ABO809)
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

NCT00963508
View directory record Official record
Conditions
Pediculosis
Interventions
Malathion gel 0.5%, Permethrin 1% rinse (Nix Crème)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Hot Springs, Arkansas • Sacramento, California • Kissimmee, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses

NCT02215707
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine
Biological
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 1Phase 2 Interventional

Cognitive Behavioral Therapy for Trichotillomania

NCT00740909
View directory record Official record
Conditions
Trichotillomania
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 25, 2026, 7:15 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults

NCT07249463
View directory record Official record
Conditions
Cryptosporidiosis
Interventions
Cryptosporidium parvum oocysts (ABO809), EDI048, Placebo
Biological · Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 7:15 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice

NCT00244439
View directory record Official record
Conditions
Lice Infestations
Interventions
MALG, Ovide (malathion) lotion 0.05%, Permethrin 1%
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Scottsdale, Arizona • Miami, Florida • St. Petersburg, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Oct 25, 2026, 7:15 PM EDT